Author: Immunovant Inc.

Posted Date:

April 2, 2026

Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Immunovant Inc.

April 2, 2026
Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

Immunovant Inc.

February 12, 2026
Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

Immunovant Inc.

January 28, 2026